Status:
UNKNOWN
The Role of m6A RNA Modification in Moyamoya Disease
Lead Sponsor:
Beijing Tiantan Hospital
Conditions:
Moyamoya Disease
Eligibility:
All Genders
4-60 years
Brief Summary
The purpose of this study is to detect the change of m6A RNA modification from peripheral blood of patients with moyamoya disease, and to assess the relationship between clinical characteristics.
Detailed Description
Moyamoya disease (MMD) is a rare cerebrovascular disorder characterized by occlusion of bilateral internal carotid and intracerebral arteries with the compensatory growth of fragile small vessels. The...
Eligibility Criteria
Inclusion
- Health volunteers' inclusion criteria:
- Age between 4-60; Male or female;
- Exclusion criteria:
- Exclude the volunteers with history of cerebrovascular disease.
Exclusion
Key Trial Info
Start Date :
January 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT04696094
Start Date
January 1 2021
End Date
December 31 2022
Last Update
February 17 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Tiantan Hospital Capital Medical University
Beijing, Beijing Municipality, China